Suzanne C van Es1, Adrienne H Brouwers2, Shekar V K Mahesh3, Annemarie M Leliveld-Kors4, Igle J de Jong4, Marjolijn N Lub-de Hooge5, Elizabeth G E de Vries1, Jourik A Gietema1, Sjoukje F Oosting6. 1. Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. 2. Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. 3. Department of Radiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. 4. Department of Urology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; and. 5. Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. 6. Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands s.oosting@umcg.nl.
Abstract
Currently, biomarkers that predict the efficacy of everolimus in metastatic renal cell carcinoma (mRCC) patients are lacking. Everolimus inhibits vascular endothelial growth factor A (VEGF-A) expression. We performed PET scans on mRCC patients with 89Zr-bevacizumab, a VEGF-A-binding antibody tracer. The aims were to determine a change in tumor tracer uptake after the start of everolimus and to explore whether 89Zr-bevacizumab PET can identify patients with early disease progression. Methods: 89Zr-bevacizumab PET was done before and 2 and 6 wk after the start of everolimus, 10 mg/d, in mRCC patients. Routine CT scans were performed at baseline and every 3 mo thereafter. Tumor tracer uptake was quantified using SUVmax The endpoints were a change in tumor tracer uptake and treatment response on CT after 3 mo. Results: Thirteen patients participated. The median SUVmax of 94 tumor lesions was 7.3 (range, 1.6-59.5). Between patients, median tumor SUVmax varied up to 8-fold. After 2 wk, median SUVmax was 6.3 (1.7-62.3), corresponding to a mean decrease of 9.1% (P < 0.0001). Three patients discontinued everolimus early. At 6 wk, a mean decrease in SUVmax of 23.4% compared with baseline was found in 70 evaluable lesions of 10 patients, with a median SUVmax of 5.4 (1.1-49.4, P < 0.0001). All 10 patients who continued treatment had stable disease at 3 mo. Conclusion: Everolimus decreases 89Zr-bevacizumab tumor uptake. Further studies are warranted to evaluate the predictive value of 89Zr-bevacizumab PET for everolimus antitumor efficacy.
Currently, biomarkers that predict the efficacy of everolimus in metastatic renal cell carcinoma (mRCC) patients are lacking. Everolimus inhibits vascular endothelial growth factor A (VEGF-A) expression. We performed PET scans on mRCC patients with 89Zr-bevacizumab, a VEGF-A-binding antibody tracer. The aims were to determine a change in tumor tracer uptake after the start of everolimus and to explore whether 89Zr-bevacizumab PET can identify patients with early disease progression. Methods: 89Zr-bevacizumab PET was done before and 2 and 6 wk after the start of everolimus, 10 mg/d, in mRCC patients. Routine CT scans were performed at baseline and every 3 mo thereafter. Tumor tracer uptake was quantified using SUVmax The endpoints were a change in tumor tracer uptake and treatment response on CT after 3 mo. Results: Thirteen patients participated. The median SUVmax of 94 tumor lesions was 7.3 (range, 1.6-59.5). Between patients, median tumor SUVmax varied up to 8-fold. After 2 wk, median SUVmax was 6.3 (1.7-62.3), corresponding to a mean decrease of 9.1% (P < 0.0001). Three patients discontinued everolimus early. At 6 wk, a mean decrease in SUVmax of 23.4% compared with baseline was found in 70 evaluable lesions of 10 patients, with a median SUVmax of 5.4 (1.1-49.4, P < 0.0001). All 10 patients who continued treatment had stable disease at 3 mo. Conclusion:Everolimus decreases 89Zr-bevacizumabtumor uptake. Further studies are warranted to evaluate the predictive value of 89Zr-bevacizumab PET for everolimus antitumor efficacy.
Authors: Wojciech G Lesniak; Chengyan Chu; Anna Jablonska; Yong Du; Martin G Pomper; Piotr Walczak; Miroslaw Janowski Journal: J Nucl Med Date: 2018-10-12 Impact factor: 10.057
Authors: Kornelis S M van der Geest; Maria Sandovici; Pieter H Nienhuis; Riemer H J A Slart; Peter Heeringa; Elisabeth Brouwer; William F Jiemy Journal: Front Med (Lausanne) Date: 2022-06-06
Authors: Anna G Sorace; Asser A Elkassem; Samuel J Galgano; Suzanne E Lapi; Benjamin M Larimer; Savannah C Partridge; C Chad Quarles; Kirsten Reeves; Tiara S Napier; Patrick N Song; Thomas E Yankeelov; Stefanie Woodard; Andrew D Smith Journal: Semin Nucl Med Date: 2020-06-10 Impact factor: 4.446
Authors: Ravindra A De Silva; Michael A Gorin; Ronnie C Mease; Il Minn; Ala Lisok; Donika Plyku; Sridhar Nimmagadda; Mohamad E Allaf; Xing Yang; George Sgouros; Steven P Rowe; Martin G Pomper Journal: J Labelled Comp Radiopharm Date: 2021-03-04 Impact factor: 1.921